China’s Hua Medicine plans $400 million Hong Kong IPO, led by Goldman: sources

HONG KONG (Reuters) – Chinese drug developer Hua Medicine is planning to raise at least $400 million in an initial public offer in Hong Kong in the latest in a series of biotech floats in the city, said people with knowledge of the matter. Hong Kong is …
( read original story …)


Related Post

Global luxury brands again chase China’s you...
views 7
HONG KONG (Reuters) - Global luxury brands from Pr...
Poly Property Wins Kowloon Residential Site for HK...
views 14
The Hong Kong Lands Department on Wednesday announ...
Hong Kong democracy movement bides its time in fac...
views 21
"Hong Kong used to be special," said a man who onl...
Hong Kong green groups call for endangered species...
views 21
Hong Kong conservationists are calling for wildlif...
Trump aims sanctions at Iran … Hong Kong ban...
views 19
Chandran Nair, the founder of the Global Institute...
Maria Cordero, Hong Kong music and movie star, per...
views 21
Singer Maria Cordero is a regular on Hong Kong tel...
Life after death – in a subdivided flat: why paper...
views 26
To Chiu-sung holds up a 20cm tall, three-storey ca...
Can Hong Kong learn from how South Africa’s Cape T...
views 26
Hong Kong has much to learn about conservation fro...
Young professionals are leaving Hong Kong in drove...
views 28
“The whole environment here is almost opposite to ...
Hong Kong-Macau-Zhuhai bridge will close property ...
views 34
The opening of the Hong Kong-Zhuhai-Macau bridge l...